January 18, 2022
Shionogi said on January 17 that it has kicked off a Japanese PIII trial designed to compare neutralizing antibody titers between its COVID-19 vaccine S-268019 and AstraZeneca’s Vaxzevria. The active-control comparative study will look into neutralizing antibody titers in 1,000...read more